Table 3.
Duration in days of the different clinical manifestations, comparison of children with confirmed infection by SARS-CoV-2 and children in who the infection had been suspected but not confirmed.
| Symptoms | SARS-CoV-2 group, n = 33 | Uninfected group, n = 93 | P |
|---|---|---|---|
| Duration in days, median (IQR) | Duration in days, median (IQR) | ||
| Cough | 10.0 (6.0–15.0) | 9.0 (3.7–15.0) | .531 |
| Anosmia/hyposmia | 10.0 (7.5–12.5) | 7.0 (5.0–20.0)a | .759 |
| Dysgeusia | 10.0 (3.2–13.7) | 4.5 (3.0–5.5) | .197 |
| Wheezing | 9.0 (2.7–16.5) | 7.5 (4.0–14.2) | .864 |
| Rhinorrhoea | 8.0 (8.0–15.0) | 10.0 (3.0–15.0) | .638 |
| Odynophagia | 7.0 (4.2–9.7) | 6.0 (2.0–7.0) | .116 |
| Myalgia | 5.0 (3.5–10.5) | 3.0 (2.0–6.5) | .070 |
| Asthenia | 4.0 (2.0–10.0) | 5.0 (2.0–7.2) | .847 |
| Headache | 4.0 (2.7–10.2) | 3.5 (2.7–7.0) | .551 |
| Chills | 4.0 (1.0–7.2) | 3.0 (2.0–4.0) | .859 |
| Fever | 3.0 (2.0–7.2) | 4.0 (2.0–7.0) | .596 |
| Diarrhoea | 3.0 (2.0–3.5) | 2.0 (1.0–2.0) | .080 |
| Abdominal pain | 2.5 (2.0–2.7) | 4.0 (2.5–6.0) | .261 |
| Difficulty breathing | 2.0 (1.0–3.0) | 4.0 (2.0–7.0) | .115 |
| Vomiting | NA | 1.5 (1.0–3.0) | NA |
Ordered by decreasing duration.
IQR, interquartile range; NA, not applicable.
a
One patient in the uninfected group reported anosmia lasting 40 days.